Trial reportDiabetes, obesity & metabolism2020
The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.
Trial report in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Interventions associated with brown adipose tissue activation and the impact on energy expenditure and weight loss: A systematic review.Frontiers in endocrinology · 2022Pooled it
- Stimulation of the beta-2-adrenergic receptor with salbutamol activates human brown adipose tissue.Cell reports. Medicine · 2023Trial
- The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.Diabetes, obesity & metabolism · 2020Trial
- Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk.Current obesity reports · 2026Review
- A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism.JCI insight · 2026Article
- Decoding Adipose Tissue Phenotypic Switching: From Mechanisms to Computational Drug Discovery.Current obesity reports · 2026Review
- Reexamining Fat: Exploring Diversity, Plasticity, Development, Functional Implication, and Therapeutic Options.International journal of molecular sciences · 2026Review
- Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Dlat-Trpv3 pathway by hyperforin elicits non-canonical promotion of adipose thermogenesis as an effective anti-obesity strategy.Journal of advanced research · 2025Article
- Circulating FGF21 is lower in South Asians compared with Europids with type 2 diabetes mellitus.Endocrine connections · 2025Article
- Emerging debates and resolutions in brown adipose tissue research.Cell metabolism · 2025Review
- Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition.Frontiers in pharmacology · 2025Article
- Physiological and metabolic functions of the βJournal of physiology and biochemistry · 2024Review
- UCP1 expression in human brown adipose tissue is inversely associated with cardiometabolic risk factors.European journal of endocrinology · 2024Article
- Brown Adipose Tissue Activation in Humans Increases Plasma Levels of Lipid Mediators.The Journal of clinical endocrinology and metabolism · 2024Article
- Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.Journal of clinical medicine · 2023Review
- Pharmacological antagonism of receptor for advanced glycation end products signaling promotes thermogenesis, healthful body mass and composition, and metabolism in mice.Obesity (Silver Spring, Md.) · 2023Article
- Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans.Cardiovascular research · 2023Review
- Brown Adipose Tissue-A Translational Perspective.Endocrine reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 3 countries.
Funding
Abstract
aimTo compare the effects of cold exposure and the β3-adrenergic receptor agonist mirabegron on plasma lipids, energy expenditure and brown adipose tissue (BAT) activity in South Asians versus Europids. MATERIALS AND
methodsTen lean Dutch South Asian (aged 18-30 years; body mass index [BMI] 18-25 kg/m
resultsIn both ethnicities, cold exposure increased the levels of several serum lipid species, whereas mirabegron only increased free fatty acids. Cold exposure increased lipid oxidation in both ethnicities, while mirabegron increased lipid oxidation in Europids only. Cold exposure and mirabegron enhanced supraclavicular skin temperature in both ethnicities. Cold exposure decreased BAT fat fraction in both ethnicities. After the combination of data from both ethnicities, mirabegron decreased BAT fat fraction compared with placebo.
conclusionsIn South Asians and Europids, cold exposure and mirabegron induced beneficial metabolic effects. When combining both ethnicities, cold exposure and mirabegron increased REE and lipid oxidation, coinciding with a higher supraclavicular skin temperature and lower BAT fat fraction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.